Clinical Trial Update: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of TBio-6517 alone or in combination with pembrolizumab in solid tumors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Cutaneous Squamous Cell Carcinoma
• Hpv-positive Oropharyngeal Squamous Cell Carcinoma
• Melanoma
• Mesothelioma
• Renal Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TBio-6517

Snippet

Sponsor: Turnstone Biologics, Corp. | Conditions: Solid Tumor, Microsatellite Stable Colorectal Cancer | Phase 1 | Status: TERMINATED